Dolutegravir (DTG) is recommended and widely used during pregnancy for maternal viral suppression and preventing perinatal transmission of HIV. Our objective is to assess pregnancy and neonatal outcomes including birth defects following prenatal DTG use using real-world European data.
Dolomite-EPPICC is a multi-cohort European observational study of DTG use in pregnant women living with HIV and their infants. An analysis of prospectively collected data on all pregnancies with any prenatal DTG exposure and with birth outcomes was conducted among participating cohorts from Italy,
Authors: C Thorne, K Aebi-Popp, L Ene, M Floridia, AM Gamell, M Illan, H Peters, A Samarina, L Ragone, C Giaquinto, V Vannappagari
Presented at: CROI 2022